■	Overall,	40.9%	(312/763)	of	patients	achieved	complete	disease	clearance	at	
least	once	during	the	study;	this	included	233	patients	who	entered	the	study	
with	a	Physician	Global	Assessment	(PGA)	score	of	≥1	and	79	patients	who	
entered	with	a	PGA	of	04

■	The	median	duration	of	remittive	effect	while	off	therapy	for	patients	who	
entered	the	study	with	a	PGA	of	0	was	115	days,	and	the	mean	total	duration	
of	remittive	effect	off	therapy	for	patients	who	entered	with,	or	achieved,	a	
PGA	of	0	was	130	days4	

■	Durability	of	response	of	up	to	52	weeks	was	demonstrated	with	intermittent	
use	of	tapinarof	cream	1%	QD,	indicating	no	observation	of	tachyphylaxis	
(defined	as	loss	of	response)	while	on	therapy4

■	Tapinarof	cream	1%	QD	was	well	tolerated	with	long-term	use	and	had	a	safety	
profile	consistent	with	previous	studies2,5

 RESULTS
Patient Satisfaction Questionnaire  
■	91.6%	of	eligible	patients	(n=763)	completing	PSOARING	1	and	2	elected	to	

enroll	in	PSOARING	3

■	Patient	Satisfaction	Questionnaires	were	completed	by	78.5%	(599/763)	of	
patients	in	PSOARING	3

■	Patients	consistently	reported	high	satisfaction	rates	across	all	parameters,	
including	patients’	satisfaction	with	tapinarof	efficacy,	formulation	elegance,	
application	ease,	impact	on	daily	life,	and	preference	for	tapinarof	cream	versus	
prior	psoriasis	therapies	

Confidence and Satisfaction with the Efficacy of Tapinarof Cream   
■	Most	patients	either	strongly	agreed	or	agreed	with	all	questions	on	confidence	

and	satisfaction	with	the	efficacy	of	tapinarof	cream	(Figure 3)
■	85.8%	felt	they	could	easily	manage	their	psoriasis	with	tapinarof,	and	83.6%	

were	satisfied	with	how	well	tapinarof	worked	

■	In	addition	to	the	40.9%	of	patients	who	achieved	complete	disease	clearance	
and	the	observed	remittive	effect	of	~4	months,	62.9%	of	patients	either	
strongly	agreed	or	agreed	that	tapinarof	cleared	their	skin	and	kept	psoriasis	
from	coming	back

■	84.1%	had	confidence	in	tapinarof,	and	84.0%	would	recommend	tapinarof	to	
other	patients	with	psoriasis

■	82.5%	of	patients	would	use	tapinarof	again	or	continue	on	tapinarof	if	it		
was	available

Figure 3. Confidence and Satisfaction with the Efficacy of Tapinarof Cream 
(n=599)

Ease of Application and Cosmetic Elegance of Tapinarof Cream
■	Patients	were	consistently	very	satisfied	with	the	tapinarof	cream	formulation	

and	elegance	(Figure 4)
■	93.2%	were	satisfied	with	the	time	spent	applying	tapinarof,	and	96.3%	

considered	it	easy	to	apply	

■	In	addition,	most	patients	either	strongly	agreed	or	agreed	that	tapinarof	was	quickly	
absorbed	(89.5%),	felt	good	on	their	skin	(79.9%),	and	was	not	greasy	(89.0%)

■	87.7%	were	very	satisfied	with	the	look	and	feel	of	tapinarof	

Figure 4. Ease of Application and Cosmetic Elegance of Tapinarof Cream 
(n= 599) 

*n	number	for	question	is	598.	†n	number	for	question	is	587.

Patient Satisfaction with Tapinarof Cream 1% Once Daily for Plaque Psoriasis  
in a Long-Term Extension Trial

Jerry Bagel,1 Linda Stein Gold,2 James Del Rosso,3 Neal Bhatia,4 Sandy Johnson,5 Paul Yamauchi,6 Angela Y. Moore,7 Anna M. Tallman8
1Psoriasis Treatment Center of Central New Jersey, East Windsor, NJ, USA; 2Henry Ford Health System, Detroit, MI, USA; 3JDR Dermatology Research/Thomas Dermatology, Las Vegas, NV, USA and Advanced Dermatology & Cutaneous Surgery, Maitland, FL, USA;  

4Therapeutics Clinical Research, San Diego, CA, USA; 5Johnson Dermatology, Fort Smith, AR, USA; 6Dermatology Institute & Skin Care Center, Santa Monica, CA, USA; 7Arlington Center for Dermatology, Arlington Research Center, Arlington, TX, USA; 8Dermavant Sciences, Inc., Morrisville, NC, USA

 BACKGROUND
■	Patient	dissatisfaction	with	current	therapies	is	an	important	barrier	to	optimal	

care	of	psoriasis	(52%	of	psoriasis	patients	have	reported	dissatisfaction	with	
their	treatment1)	and	there	is	a	need	for	efficacious,	tolerable,	easy-to-use	topical	
therapies	that	can	be	used	long	term,	including	on	sensitive	skin	areas

■	Tapinarof	1%	is	a	cosmetically	elegant,	once	daily	(QD)	topical	cream	that	does	
not	contain	added	fragrance	and	is	free	of	petrolatum,	parabens,	and	gluten.		
The	vehicle	is	specifically	designed	to	reduce	skin	irritation	and	optimize	the	
delivery	of	tapinarof	to	the	target	site

■	Tapinarof	cream	1%	QD	demonstrated	significant	efficacy	and	was	well	tolerated	
in	two	12-week	pivotal	phase	3	trials	of	1,025	adults	with	mild-to-severe	plaque	
psoriasis,		PSOARING	1	(NCT03956355)	and	PSOARING	2	(NCT03983980),		
and	demonstrated	favorable	patient-reported	local	tolerability	and		
investigator-assessed	irritation	scores	including	sensitive	skin	areas2,3

■	PSOARING	3	(NCT04053387)	was	a	40-week,	long-term,	open-label	extension	
trial	to	assess	the	efficacy,	durability	of	response	on	therapy,	duration	of	
remittive	effect	off	therapy,	safety,	and	tolerability	of	tapinarof	cream	1%	QD

■	Figure 1 displays	photographs	of	the	clinical	response	of	a	patient	treated		
with	tapinarof	1%	QD	who	achieved	primary	and	secondary	efficacy,	and	
patient-reported	outcome	(PRO)	endpoints

Figure 1. Clinical Response of a Patient with Plaque Psoriasis who Achieved 
Primary and Secondary Efficacy, and PRO Endpoints

PGA	and	PASI	are	global	efficacy	assessments.	Example	of	one	representative	target	lesion	of	one	tapinarof-treated	patient	
from	PSOARING	1	clinical	trial.	

*DLQI	was	assessed	at	baseline,	Week	4	(no	evaluation	at	Week	8),	and	Week	12.

DLQI,	Dermatology	Life	Quality	Index;	PASI,	Psoriasis	Area	and	Severity	Index;	PGA,	Physician	Global	Assessment;		
PP-NRS,	Peak	Pruritus	Numeric	Rating	Scale.	

 OBJECTIVE
■	Given	that	patient	dissatisfaction	with	current	therapies	has	a	significant	impact	

on	disease	management,	we	assessed	patient	satisfaction	using	a	Patient	
Satisfaction	Questionnaire;	here	we	present	the	results	from	PSOARING	3,	a	
long-term,	open-label	extension	trial	of	tapinarof	cream	1%	QD

 METHODS
Study Design
■	Patients	completing	PSOARING	1	and	PSOARING	2	were	eligible	to	enroll	in	

PSOARING	3	for	up	to	40	weeks	of	open-label	treatment	with	tapinarof	cream	
1%	QD,	followed	by	4	weeks	of	follow-up	(Figure 2)	

■	The	Patient	Satisfaction	Questionnaire	was	designed	to	assess	patients’	
satisfaction	with	tapinarof	efficacy,	formulation	elegance,	application	ease,		
impact	on	daily	life,	and	preference	for	tapinarof	cream	versus	prior		
psoriasis	therapies

	 –			The	questionnaire	included	a	series	of	18	questions	with	responses	on	a		
scale	of	strongly	agree,	agree,	neutral,	disagree,	or	strongly	disagree	

■	Patient	Satisfaction	Questionnaire	responses	were	assessed	at	Week	40		
(or	Early	Termination	Visit)	and	summarized	overall

Figure 2. PSOARING 3 Study Design

Four	patients	(3	tapinarof,	1	vehicle)	did	not	have	a	baseline	PGA	and	are	listed	as	missing.		
PGA,	Physician	Global	Assessment;	QD,	once	daily.	

Previously Reported Efficacy Outcomes from PSOARING 3 
■	Tapinarof	cream	1%	QD	demonstrated	continued	and	substantial	improvement	

in	efficacy	with	long-term	use,	beyond	the	improvements	already	observed	in	
the	12-week	pivotal	trials,	PSOARING	1	and	22,4

• PGA=4
• PASI=18.4

• DLQI=16
• PP-NRS=6

• PGA=2
• PASI=0.9

• DLQI=4*
• PP-NRS=0

• PGA=1
• PASI=0.6

• DLQI=1
• PP-NRS=0

BASELINE WEEK 8 WEEK 12

Off treatment

Off treatment

PGA=0
(n=79)

PGA=0
Stop treatment

PGA≥2
Re-start treatment

PGA≥1
(n=680)

Tapinarof 1% QD Pivotal
(n=508)

Tapinarof 1% QD

Vehicle QD Pivotal
(n=255)

Long-term open-label extension
(40 weeks)

Follow-up
(4 weeks)

Double-blind
treatment
(12 weeks)

85.8

4.5
2.5

7.2

Easily manage 
psoriasis with 

tapinarof

83.6

6.3
2.3

7.7

Satisfied with 
how well 

tapinarof worked

84.1

5.2
1.5

9.2

Have confidence 
in tapinarof

62.9

12.5

5.2

19.4

Tapinarof cleared skin 
and prevented psoriasis 

from coming back

84.0

4.2 2.3

9.5

If available would 
recommend 

tapinarof to others

82.5

6.2
3.2

8.2

If available would 
use tapinarof again 

or continue on it

P
ro

p
o

rt
io

n
 o

f 
p

a
ti

e
n

ts
, 

%

30

40

70

80

90

100

60

50

20

10

0

Strongly Agree + Agree
Neutral
Disagree
Strongly Disagree

96.3

0.5 0.5
2.7

93.2

2.0 0.7
4.2

89.0

2.5 0.5

8.0

89.5

2.0 0.3

8.2

79.9

2.2 0.8

17.1

87.7

1.7 0.3

10.2

P
ro

p
o

rt
io

n
 o

f 
p

a
ti

e
n

ts
, 

%

30

40

70

80

90

100

60

50

20

10

0
Tapinarof was 
easy to apply

Time spent applying 
was acceptable and did 
not impact everyday life

Tapinarof was 
not greasy

Tapinarof quickly 
absorbs

Tapinarof feels 
good on skin*

Satisfied with 
look and feel of 

tapinarof†

Strongly Agree + Agree
Neutral
Disagree
Strongly Disagree

Strongly Agree + Agree
Neutral
Disagree
Strongly Disagree

81.7

4.2
1.9

12.1

65.3

2.9
0.6

31.2

81.1

4.2
1.5

13.1

55.3

12.6

7.0

25.1

63.8

10.1

4.5

21.6

67.8

11.1

4.5

16.6

P
ro

p
o

rt
io

n
 o

f 
p

a
ti

e
n

ts
, 
%

a. Versus prior topical therapies (n=519) b. Versus prior systemic therapies (n=199)

30

40

70

80

90

100

60

50

20

10

0
Tapinarof was 
more effective 

than topical drugs 
I have used in the 

past

Tapinarof was 
easier to use than 

topical drugs I 
have used in the 

past

I prefer tapinarof 
to topical drugs I 
have used in the 

past

Tapinarof was 
more effective than 

systemic drugs I 
have used in the 

past

Tapinarof was 
easier to use than 
systemic drugs I 
have used in the 

past

I prefer tapinarof 
to systemic drugs 
I have used in the 

past

Preference for Tapinarof Cream Versus Prior Topical Psoriasis Therapies   
■	For	patients	who	reported	having	used	other	topical	drugs	to	treat	psoriasis	in	

the	past,	81.7%	considered	tapinarof	to	be	more	effective	than	prior	therapies,	
and	65.3%	considered	tapinarof	easier	to	use	(Figure 5a)

■	81.1%	of	patients	preferred	tapinarof	to	other	topical	drugs	used	to	treat	their	
psoriasis	in	the	past

Preference for Tapinarof Cream Versus Prior Systemic Psoriasis Therapies      
■	For	patients	who	reported	having	used	systemic	drugs	to	treat	psoriasis	in	the	

past,	55.3%	considered	tapinarof	to	be	more	effective	than	prior	therapies,	and	
63.8%	considered	tapinarof	to	be	easier	to	use	(Figure 5b)

■	Most	patients	(67.8%)	also	preferred	tapinarof	to	systemic	drugs	used	to	treat	
their	psoriasis	in	the	past

Figure 5. Patient Preference for Tapinarof Cream Versus Prior Topical and 
Systemic Therapies

 CONCLUSION
■	Patient satisfaction data from PSOARING 3 demonstrate a consistent and 

highly positive perception of tapinarof cream 1% QD across all patient relevant 
parameters, including satisfaction with tapinarof efficacy, formulation elegance, 
application ease, impact on daily life, and preference for tapinarof cream versus 
prior psoriasis therapies

 REFERENCES
1.	Armstrong	AW,	et	al.	JAMA Dermatol.	2013;149:1180–1185;	2.	Lebwohl	M,	et	
al.	N Engl J Med.	2021;385:2219–2229;	3.	Bissonnette	R,	et	al.	Poster	presented	
at:	International	Federation	of	Psoriasis	Associations;	June	30–July	3,	2021;	
Virtual;	4.	Strober	B,	et	al.	Oral	presented	at:	European	Academy	of	Dermatology	
and	Venereology;	September	30,	2021;	Virtual;	5.	Robbins	K,	et	al.	J Am Acad 
Dermatol.	2019;80:714–721.	

 ACKNOWLEDGMENTS
Trials	were	funded	by	Dermavant	Sciences,	Inc.	and	the	authors	thank	the	
investigators,	patients	and	their	families,	and	colleagues	involved	in	their	conduct.	
J.B.	has	received	research	funds	payable	to	Psoriasis	Treatment	Center	and/or	
speaking/consultant	fees	from	AbbVie,	Amgen,	Arcutis	Biotherapeutics,	Boehringer	
Ingelheim,	Bristol	Myers	Squibb,	Celgene,	Corrona	LLC,	Dermavant	Sciences,	
Ltd,	Dermira/UCB,	Eli	Lilly,	Glenmark	Pharmaceuticals	Ltd,	Janssen	Biotech,	
Kadmon	Corporation,	LEO	Pharma,	Lycera	Corp,	Menlo	Therapeutics,	Novartis,	
Pfizer,	Regeneron,	Sun	Pharma,	Taro	Pharmaceutical	Industries	Ltd,	UCB,	and	
Valeant	Pharmaceuticals.	L.S.G.	has	served	as	a	consultant,	and/or	has	received	
payment	for	the	development	of	educational	presentations,	and/or	has	received	
grants	from	Arcutis,	Amgen,	Bristol	Myers	Squibb,	Dermavant	Sciences,	Inc.,	Eli	
Lilly,	LEO	Pharma,	Ortho	Dermatologic,	and	UCB	Biopharma.	J.D.R.	is	a	consultant	
and	research	investigator	for	Dermavant	Sciences,	Inc.	N.B.	is	a	consultant	with	
honorarium	and	an	investigator	for	Dermavant	Sciences,	Inc.	SJ	is	an	advisor	
and/or	speaker	and/or	editor	and/or	involved	in	clinical	trials	for	AbbVie,	Aclaris,	
AFMC,	Allergan,	Candela	Syneron,	Cassiopea,	Celgene,	Amgen,	Chemocentryx,	
Dermavant	Sciences,	Inc.,	Dermira,	Foamix,	Gage,	Galderma,	GSK,	Journal	of	
Arkansas	Medical	Society,	LEO,	Eli	Lilly,	National	Psoriasis	Foundation,	Nielsen,	
Novartis,	Practical	Dermatology,	Regeneron,	Sanofi	Genzyme,	Skin	Medical,	
TARGET	Therapeutics,	and	the	University	of	Pennsylvania.	P.Y.	has	served	as	an	
investigator	and/or	speaker	and/or	consultant	for	AbbVie,	Amgen,	Arcutis,	BMS,	
Dermavant,	EPI	Health,	Incyte,	Janssen,	Lilly,	Leo,	Novartis,	Pfizer,	Sun	Pharma,	
and	UCB.	A.Y.M.	has	served	as	an	investigator	for	Dermavant	Sciences,	Inc.	
A.M.T.	is	an	employee	of	Dermavant	Sciences	Inc.,	with	stock	options.	Editorial	
and	medical	writing	support	under	the	guidance	of	the	authors	was	provided	by	
ApotheCom,	UK,	and	was	funded	by	Dermavant	Sciences,	Inc.	in	accordance	with	
Good	Publication	Practice	(GPP3)	guidelines	(Ann Intern Med.	2015;163:461–464).

Contact	Dr	Bagel	at	dreamacres1@aol.com	with	questions	or	comments.